EDINBURGH, Oct. 2, 2020
EDINBURGH, Oct. 2, 2020 /PRNewswire/ --This long-term health economic analysis was performed to establish the cost-effectiveness for funding of the Dexcom G6 versus fingerstick testing. It examines UK-based type 1 diabetes (T1D) patients with elevated HbA1c. These elevated levels can increase the risk of developing diabetes-related complications. The Dexcom G6 falls well below the cost-effectiveness threshold set by NICE in order to be recommended for NHS funding.
PDF - https://mma.prnewswire.com/media/1305734/DexCom_Infographic.pdf
Logo - https://mma.prnewswire.com/media/553571/Dexcom_Logo.jpg
Photo - https://mma.prnewswire.com/media/1305607/DexCom_Infographic.jpg